<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36774332</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1783</StartPage><EndPage>1790</EndPage><MedlinePgn>1783-1790</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2023.02.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(23)00134-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">The relationship between coronavirus disease 2019 (COVID-19) vaccination and long COVID has not been firmly established. We conducted a systematic review and meta-analysis to evaluate the association between COVID-19 vaccination and long COVID.</AbstractText><AbstractText Label="METHODS">PubMed and EMBASE databases were searched on September 2022 without language restrictions (CRD42022360399) to identify prospective trials and observational studies comparing patients with and without vaccination before severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We also included studies reporting symptomatic changes of ongoing long COVID following vaccination among those with a history of SARS-CoV-2 infection. Odds ratios (ORs) for each outcome were synthesized using a random-effects model. Symptomatic changes after vaccination were synthesized by a one-group meta-analysis.</AbstractText><AbstractText Label="RESULTS">Six observational studies involving 536,291 unvaccinated and 84,603 vaccinated (before SARS-CoV-2 infection) patients (mean age, 41.2-66.6; female, 9.0-67.3%) and six observational studies involving 8,199 long COVID patients (mean age, 40.0 to 53.5; female, 22.2-85.9%) who received vaccination after SARS-CoV-2 infection were included. Two-dose vaccination was associated with a lower risk of long COVID compared to no vaccination (OR, 0.64; 95% confidence interval [CI], 0.45-0.92) and one-dose vaccination (OR, 0.60; 95% CI, 0.43-0.83). Two-dose vaccination compared to no vaccination was associated with a lower risk of persistent fatigue (OR, 0.62; 95% CI, 0.41-0.93) and pulmonary disorder (OR, 0.50; 95% CI, 0.47-0.52). Among those with ongoing long COVID symptoms, 54.4% (95% CI, 34.3-73.1%) did not report symptomatic changes following vaccination, while 20.3% (95% CI, 8.1-42.4%) experienced symptomatic improvement after two weeks to six months of COVID-19 vaccination.</AbstractText><AbstractText Label="CONCLUSIONS">COVID-19 vaccination before SARS-CoV-2 infection was associated with a lower risk of long COVID, while most of those with ongoing long COVID did not experience symptomatic changes following vaccination.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Atsuyuki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hospital Medicine, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwagami</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Health Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasuhara</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Cardiovascular Research, The Abigail Wexner Research Institute and The Heart Center, Nationwide Children's Hospital, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Hisato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA. Electronic address: tkuno@montefiore.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>22</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36774332</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pii">S0264-410X(23)00134-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard 2022. https://covid19.who.int/ (accessed March 10, 2022).</Citation></Reference><Reference><Citation>Levine R.L. Addressing the Long-term Effects of COVID-19. JAMA. 2022;328:823&#x2013;824. doi: 10.1001/jama.2022.14089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.14089</ArticleId><ArticleId IdType="pubmed">35921084</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374 doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L., Drake T.M., Pauley E., Jesudason E.C., Olliaro P., Lim W.S., et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Reg Health Eur. 2021;8 doi: 10.1016/j.lanepe.2021.100186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100186</ArticleId><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P.L.B.J., van Jaarsveld C.H.M. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39:159&#x2013;167. doi: 10.1093/fampra/cmab076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., de Oliveira M.H.S., Peligro P.J., Velasco J.V., Macaranas I., Ver A.T., et al. Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis. J Clin Med Res. 2022;11 doi: 10.3390/jcm11247314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247314</ArticleId><ArticleId IdType="pmc">PMC9787827</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020;69:993&#x2013;8. 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Ver A.T., Velasco J.V., Pastrana A., Catahay J.A., Salvagno G.L., et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022;59:373&#x2013;390. doi: 10.1080/10408363.2022.2038539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2022.2038539</ArticleId><ArticleId IdType="pmc">PMC8935447</ArticleId><ArticleId IdType="pubmed">35220860</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Guerrero-Arguero I., Velasco J.V., Ver A.T., Santos de Oliveira M.H., Catahay J.A., et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J Med Virol. 2022;94:2939&#x2013;2961. doi: 10.1002/jmv.27688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27688</ArticleId><ArticleId IdType="pmc">PMC9088566</ArticleId><ArticleId IdType="pubmed">35229324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal M., Abo Omirah M., Hussein A., Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021;75:e13746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536922</ArticleId><ArticleId IdType="pubmed">32991035</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J., Andrews N., Gower C., Robertson C., Stowe J., Tessier E., et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373 doi: 10.1136/bmj.n1088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1088</ArticleId><ArticleId IdType="pmc">PMC8116636</ArticleId><ArticleId IdType="pubmed">33985964</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif N., Alzahrani K.J., Ahmed S.N., Dey S.K. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol. 2021;12 doi: 10.3389/fimmu.2021.714170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.714170</ArticleId><ArticleId IdType="pmc">PMC8542872</ArticleId><ArticleId IdType="pubmed">34707602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Do vaccines protect against long COVID? What the data say. Nature. 2021;599:546&#x2013;548. doi: 10.1038/d41586-021-03495-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03495-2</ArticleId><ArticleId IdType="pubmed">34815580</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., Levi R., Sarti R., Pozzi C., Mollura M., Mantovani A., et al. Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers. JAMA. 2022 doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bermingham C., Pouwels K.B., Glickman M., Nafilyan V., Zaccardi F., et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53 doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., Moher D., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372 doi: 10.1136/bmj.n160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n160</ArticleId><ArticleId IdType="pmc">PMC8005925</ArticleId><ArticleId IdType="pubmed">33781993</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629&#x2013;634. doi: 10.1136/bmj.315.7109.629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Meza-Torres B., Delanerolle G., Okusi C., Mayor N., Anand S., Macartney J., et al. Differences in Clinical Presentation With Long COVID After Community and Hospital Infection and Associations With All-Cause Mortality: English Sentinel Network Database Study. JMIR Public Health Surveill. 2022;8:e37668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384859</ArticleId><ArticleId IdType="pubmed">35605170</ArticleId></ArticleIdList></Reference><Reference><Citation>Emecen A.N., Keskin S., Turunc O., Suner A.F., Siyve N., Basoglu Sensoy E., et al. The presence of symptoms within 6 months after COVID-19: a single-center longitudinal study. Ir J Med Sci. 2022 doi: 10.1007/s11845-022-03072-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-022-03072-0</ArticleId><ArticleId IdType="pmc">PMC9205653</ArticleId><ArticleId IdType="pubmed">35715663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. The Protective Effect of Coronavirus Disease 2019 (COVID-19) Vaccination on Postacute Sequelae of COVID-19: A Multicenter Study From a Large National Health Research Network. Open Forum Infect Dis 2022;9:ofac228. 10.1093/ofid/ofac228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., Sudre C.H., Molteni E., Berry S., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T., Hirose M., Inoue Y., Kunishima H., Otsubo T., Matsuda T. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. J Med Virol. 2022;94:3416&#x2013;3420. doi: 10.1002/jmv.27689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27689</ArticleId><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. Vaccines (Basel) 2022;10. 10.3390/vaccines10050652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Pijnenburg L, Chatelus E, Arnaud L, Gottenberg J-E, Sibilia J, et al. Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study. Vaccines (Basel) 2021;10. 10.3390/vaccines10010046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781023</ArticleId><ArticleId IdType="pubmed">35062706</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., De Martino M., Palese A., Gerussi V., Bontempo G., Graziano E., et al. Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clin Microbiol Infect. 2022;28:1140&#x2013;1148. doi: 10.1016/j.cmi.2022.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.03.016</ArticleId><ArticleId IdType="pmc">PMC8940723</ArticleId><ArticleId IdType="pubmed">35339673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg E., Han A.X., Boyd A., van Willigen H.D.G., Verveen A., Lebbink R., et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. Vaccine. 2022;40:4424&#x2013;4431. doi: 10.1016/j.vaccine.2022.05.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.090</ArticleId><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayor N., Meza-Torres B., Okusi C., Delanerolle G., Chapman M., Wang W., et al. Developing a Long COVID Phenotype for Postacute COVID-19 in a National Primary Care Sentinel Cohort: Observational Retrospective Database Analysis. JMIR Public Health Surveill. 2022;8:e36989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9374163</ArticleId><ArticleId IdType="pubmed">35861678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chudzik M., Babicki M., Kapusta J., Ka&#x142;uzi&#x144;ska-Ko&#x142;at &#x17b;., Ko&#x142;at D., Jankowski P., et al. Long-COVID Clinical Features and Risk Factors: A Retrospective Analysis of Patients from the STOP-COVID Registry of the PoLoCOV Study. Viruses. 2022;14 doi: 10.3390/v14081755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14081755</ArticleId><ArticleId IdType="pmc">PMC9415629</ArticleId><ArticleId IdType="pubmed">36016376</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A., So M., Iwagami M., Fukunaga K., Takagi H., Kabata H., et al. One-year follow-up CT findings in COVID-19 patients: A systematic review and meta-analysis. Respirology. 2022;27:605&#x2013;616. doi: 10.1111/resp.14311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.14311</ArticleId><ArticleId IdType="pmc">PMC9350074</ArticleId><ArticleId IdType="pubmed">35694728</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Harrison P.J. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154&#x2013;162. doi: 10.1016/j.bbi.2022.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen O., Waxman J.G., Makov-Assif M., Vered R., Dicker D., Hern&#xe1;n M.A., et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2022;386:1603&#x2013;1614. doi: 10.1056/NEJMoa2201688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201688</ArticleId><ArticleId IdType="pmc">PMC9020581</ArticleId><ArticleId IdType="pubmed">35417631</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro A.P.S., Feng S., Janani L., Cornelius V., Aley P.K., Babbage G., et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22:1131&#x2013;1141. doi: 10.1016/S1473-3099(22)00271-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00271-7</ArticleId><ArticleId IdType="pmc">PMC9084623</ArticleId><ArticleId IdType="pubmed">35550261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On Y.M., Goldberg Y., Mandel M., Bodenheimer O., Freedman L., Kalkstein N., et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021;385:1393&#x2013;1400. doi: 10.1056/NEJMoa2114255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114255</ArticleId><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B., Mohn K.-G.-I., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.-A., et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta J., Wiernik E., Robineau O., Carrat F., Touvier M., Severi G., et al. Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. JAMA Intern Med. 2022;182:19&#x2013;25. doi: 10.1001/jamainternmed.2021.6454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6454</ArticleId><ArticleId IdType="pmc">PMC8576624</ArticleId><ArticleId IdType="pubmed">34747982</ArticleId></ArticleIdList></Reference><Reference><Citation>Machingaidze S., Wiysonge C.S. Understanding COVID-19 vaccine hesitancy. Nat Med. 2021;27:1338&#x2013;1339. doi: 10.1038/s41591-021-01459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01459-7</ArticleId><ArticleId IdType="pubmed">34272500</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Notarte K.I., Peligro P.J., Velasco J.V., Ocampo M.J., Henry B.M., et al. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature. Viruses. 2022;14 doi: 10.3390/v14122629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122629</ArticleId><ArticleId IdType="pmc">PMC9785120</ArticleId><ArticleId IdType="pubmed">36560633</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. New Omicron-specific vaccines offer similar protection to existing boosters. Nature. 2022 doi: 10.1038/d41586-022-02806-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02806-5</ArticleId><ArticleId IdType="pubmed">36050528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>